Cargando…

Recent progress in improving the safety and efficacy of chimeric antigen receptor T cell therapy

Chimeric antigen receptor (CAR) T cell therapy has demonstrated unprecedented feat in a variety of malignancies, providing a transformative approach to treating patients with hematological malignancies and solid tumors. Although CAR-T cell therapy has shown remarkable anti-tumor activity, toxicities...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Yingying, Hu, Yongxian, Wang, Jiasheng, Huang, He
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Asia-Pacific Blood and Marrow Transplantation Group 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651329/ http://dx.doi.org/10.31547/bct-2018-003

Ejemplares similares

Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
por: Wei, Guoqing, et al.
Publicado: (2017)

Profile of capillary-leak syndrome in patients received chimeric antigen receptor T cell therapy
por: Feng, Jingjing, et al.
Publicado: (2022)

Efficacy and Safety of Chimeric Antigen Receptor T Cells in Acute Lymphoblastic Leukemia With Post-Transplant Relapse
por: Ding, Lijuan, et al.
Publicado: (2021)

Biomarkers for Chimeric Antigen Receptor T Cell Therapy in Acute Lymphoblastic Leukemia: Prospects for Personalized Management and Prognostic Prediction
por: Hong, Ruimin, et al.
Publicado: (2021)

Increasing the safety and efficacy of chimeric antigen receptor T cell therapy
por: Li, Hua, et al.
Publicado: (2017)

Ruxolitinib treatment for acute gastrointestinal graft-versus-host disease caused by donor-derived CD19-Chimeric antigen receptor T-Cell infusion in a patient with B-ALL relapsed after Allo-HSCT
por: Yang, Yingying, et al.
Publicado: (2019)

Delayed Terminal Ileal Perforation in a Relapsed/Refractory B-Cell Lymphoma Patient with Rapid Remission Following Chimeric Antigen Receptor T-Cell Therapy
por: Hu, Yongxian, et al.
Publicado: (2018)

Factors Associated with Costs in Chimeric Antigen Receptor T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies
por: Zhu, Feng, et al.
Publicado: (2020)

Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility
por: Celichowski, Piotr, et al.
Publicado: (2023)

Idiopathic thrombocytopenic purpura treatment in a relapsed/refractory multiple myeloma patient after chimeric antigen receptor T cell therapy
por: Qiu, Lei, et al.
Publicado: (2020)

Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma
por: Zu, Cheng, et al.
Publicado: (2022)

Incidence and Risk Factors Associated with Infection after Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory B-cell Malignancies
por: Zhu, Feng, et al.
Publicado: (2021)

Successful treatment of T315I BCR-ABL mutated lymphoid blast phase chronic myeloid leukemia with chimeric antigen receptor T cell therapy followed by dasatinib
por: Zhang, Hao, et al.
Publicado: (2020)

Clinical characterization and risk factors associated with cytokine release syndrome induced by COVID-19 and chimeric antigen receptor T-cell therapy
por: Hong, Ruimin, et al.
Publicado: (2020)

Clinical Characterization and Risk Factors Associated with Cytokine Release Syndrome Induced By COVID-19 and Chimeric Antigen Receptor T-Cell Therapy
por: Hong, Ruimin, et al.
Publicado: (2020)

Successful treatment of relapsed acute B-cell lymphoblastic leukemia with CD20/CD22 bispecific chimeric antigen receptor T-cell therapy
por: Liang, Zuyu, et al.
Publicado: (2020)

Strategies to Improve Chimeric Antigen Receptor Therapies for Neuroblastoma
por: Sawaisorn, Piamsiri, et al.
Publicado: (2020)

Pleural cavity cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy: A case report
por: Ding, Lijuan, et al.
Publicado: (2018)

Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
por: Hu, Yongxian, et al.
Publicado: (2016)

Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion
por: Zhang, Hao, et al.
Publicado: (2021)

Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme
por: Marei, Hany E., et al.
Publicado: (2021)

Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy for Glioblastoma: A Systemic Review and Meta-Analysis
por: Jang, Jong Keon, et al.
Publicado: (2022)

A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
por: Wang, Yiyun, et al.
Publicado: (2020)

Chimeric antigen receptor T-cell therapy
por: Burge, Cale, et al.
Publicado: (2023)

The Chimeric Antigen Receptor Detection Toolkit
por: Hu, Yifei, et al.
Publicado: (2020)

Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future
por: Li, Long, et al.
Publicado: (2020)

Lymphodepletion chemotherapy revitalizes chimeric antigen receptor T cells contributing to regression of relapsed B-cell lymphoma: A case report
por: Liang, Zuyu, et al.
Publicado: (2020)

Suicide Gene Therapy to Increase the Safety of Chimeric Antigen Receptor-Redirected T Lymphocytes
por: Casucci, Monica, et al.
Publicado: (2011)

Tumor Burden Measured by 18F-FDG PET/CT in Predicting Efficacy and Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy in Non-Hodgkin Lymphoma
por: Hong, Ruimin, et al.
Publicado: (2021)

Serial surveillance by circulating tumor DNA profiling after chimeric antigen receptor T therapy for the guidance of r/r diffuse large B cell lymphoma precise treatment
por: Zhou, Linghui, et al.
Publicado: (2021)

Chimeric Antigen Receptor T Cell Therapy in Hematology
por: Ataca, Pınar, et al.
Publicado: (2015)

Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma
por: Khurana, Arushi, et al.
Publicado: (2022)

Chimeric Antigen Receptor T-Cell Therapy and Hematopoiesis
por: Reinhardt, Bryanna, et al.
Publicado: (2023)

Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies
por: Xiao, Xinyi, et al.
Publicado: (2022)

Chimeric antigen receptor T-cell therapy for T-ALL and AML
por: Wei, Wenwen, et al.
Publicado: (2022)

Engineering better chimeric antigen receptor T cells
por: Zhang, Hao, et al.
Publicado: (2020)

Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T‐cellular therapy development
por: Kast, Johannes, et al.
Publicado: (2022)

Advances Of Chimeric Antigen Receptor T Cell Therapy In Ovarian Cancer
por: Yan, Wenying, et al.
Publicado: (2019)

Biomarkers in individualized management of chimeric antigen receptor T cell therapy
por: Du, Mengyi, et al.
Publicado: (2020)

Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma
por: Sun, Chuang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7r5uqajecf9eoo2aaidb76ouul